Trials / Completed
CompletedNCT05067478
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
Composur, a Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 403 (actual)
- Sponsor
- Urovant Sciences GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vibegron | Vibegron to be administered. |
Timeline
- Start date
- 2021-10-28
- Primary completion
- 2024-07-22
- Completion
- 2024-07-26
- First posted
- 2021-10-05
- Last updated
- 2024-12-27
Locations
64 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05067478. Inclusion in this directory is not an endorsement.